Everyone’s Talking About Pharmacogenomics. The Hard Part Is Making It Work
By Jason Peterson, RPh, Director of Clinical Strategy at Navion For decades, prescribing medication has followed a frustratingly familiar rhythm: try a […]
Articles
GLP-1 Market Update: Oral Drugs, New Formulations, Pipeline Activity, and Pricing Shifts
By Long Tran, Pharm D; Beckie Fenrick, Pharm D; and Jason Peterson, RPh New products are only part of what’s changing in the GLP-1 market. The
International Drug Sourcing Is Under Scrutiny. What Employers Should Understand Before Adopting It
By Jason Peterson, RPh, Director, Clinical Strategy & Monica Gindhart, Vice President Of Business Development For years, international sourcing—where medications are obtained
Direct-to-Consumer (DTC) Prescription Drug Programs
A Simple FAQ for Employers Several drug manufacturers now offer certain medications directly to patients at published cash prices. These
Q1 2026 Drug Updates: New FDA Approvals, Generics, and Biosimilars to Watch
By Beckie Fenrick, PharmD, MBA and Jason Peterson, RPh The first quarter of 2026 brought a steady flow of drug
What Accurate PBM Modeling Really Takes — And Why Clients Deserve More Than a Dashboard
By Greg Sanderson, VP of Analytics Over the last several years, pharmacy analytics has become increasingly visual. Dashboards, charts, and
Department of Labor Proposes New PBM Fee Disclosure Requirements for Self-Insured Health Plans
By: Beckie Fenrick, PharmD, MBA and Jason Peterson, RPh PBM compensation structures may soon face new federal transparency requirements. In
